Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools GIST

GIST

Programs, trials, and reported response and survival for gastrointestinal stromal tumor.

Data as of 11.07.2026

All drugs

Olverembatinib (HQP1351)

Stage Phase 3

Sponsor Ascentage Pharma

Route oral tablet

Modality small molecule

Class multi-kinase TKI

Mechanism kinase inhibitor; proposed p38/CD36 mechanism in SDH-deficient GIST per sponsor abstract

Target SDH-deficient GIST (no kinase driver)

Target ABL1 (approved use elsewhere) (TEC-0105)

Sources

publication, as of 2026-11-07

https://ascopubs.org/doi/10.1200/JCO.2026.44.16_suppl.11539

a total of 32 pts, including 26 pts with IHC-confirmed SDH-deficient GIST, had received olverembatinib ... Six (23.1%) pts experienced PR as best response, and the median PFS was 25.7 (range 12.9-NR) months.

J Clin Oncol 44(16_suppl) abstract 11539 (ASCO 2026), NCT03594422; congress abstract, preliminary

registry, as of 2026-11-07

https://clinicaltrials.gov/study/NCT03594422

A Phase I Study to Assess the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Properties of Oral HQP1351 in Patients With GIST or Other Solid Tumors.

ClinicalTrials.gov API v2 record, retrieved 2026-11-07

registry, as of 2026-11-07

https://clinicaltrials.gov/study/NCT06640361

A Single-Arm Registrational Phase III Study of Olverembatinib in the Treatment of Patients With SDH-Deficient Gastrointestinal Stromal Tumor (POLARIS-3)

ClinicalTrials.gov API v2 record, retrieved 2026-11-07

Studies

HQP1351SJ0003

Registry NCT03594422

Phase Phase 1

Status Recruiting

Enrollment 100

Start 2018-07-11

Primary completion 2027-12

Study completion 2028-12

Catalyst Primary completion. 12.2027. ClinicalTrials.gov primary completion date. This is a registry date, not a company readout.

Olverembatinib 30 to 50 mg every other day

Dose 30 to 50 mg

Regimen every other day

Population SDH-deficient GIST (n = 26)

Estimand Single arm

partial response as best response: 23.1%, cutoff 11.13.2025

median progression-free survival: 25.7 months, cutoff 11.13.2025

POLARIS-3

Registry NCT06640361

Phase Phase 3

Status Recruiting

Enrollment 40

Start 2024-11-11

Primary completion 2027-03-31

Study completion 2029-06-30

Catalyst Primary completion. 03.31.2027. ClinicalTrials.gov primary completion date. This is a registry date, not a company readout.